These drugs, such as monoclonal antibodies that block CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), LAG-3 (lymphocyte activation gene 3), and PD-1 or its ligand (PD-L1), restore T-cell immune responses in different cancer types [21]. This evidence concerns the gene PDCD1 and cancer.